The E27 β₂-adrenergic Receptor Polymorphism Reduces the Risk of Myocardial Infarction in Dyslipidemic Young Males

Summary

In the present study we evaluated whether two polymorphisms of β₂-adrenergic receptors (β₂-AR) gene (R16G and Q27E) could modify the risk of myocardial infarction (MI).

Using a case-control design, we analyzed the data from 125 male patients who had experienced a first episode of MI before the age of 45 years and 108 male controls matched for age. The allele frequencies for R16G and Q27E were: G16=0.56 and E27=0.36 in patients with MI and G16=0.61 and E27=0.42 in the control group. There was a trend (not statistically significant) of decreasing MI risk according to E27 or G16 alleles. Combined effect between E27 allele and history of dyslipidemia has been observed. Whereas dyslipidemia conferred a relative risk of MI of 4.8 (P<0.001) compared with normolipidemia in the entire study population, the relative risk increased to 9.0 (P<0.001) in Q27 homozygotes with dyslipidemia, and decreased to 1.8 (P=0.36) in E27 homozygotes.

Our results show that the E27 allele of the β₂-adrenergic receptor has a significant protective effect on MI in dyslipidemic young male.

Keywords

β₂-adrenergic receptor polymorphisms - myocardial infarction - dyslipidemia

• References

• 1 Reishaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the β₂-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334-9.
• 2 Buscher R, Hermann V, Insel PA. Human adrenoceptor polymorphism: evolving recognition of clinical importance. Trends Pharmacol Sci 1999; 20: 94-9.
• 3 Green SA, Turki J, Bejarano P, Hall JP, Liggett SB. Influence of β₂-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13: 25-33.
• 4 Green SA, Cole G, Jacinto M, Innis M, Liggett SB. Amino-terminal polymorphisms of the human β₂-adrenergic receptor impart distinct agonist-promoted regulatoy properties. Biochemistry. 1994; 33: 9414-9.
• 5 Ligget SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. The Ile 164 β₂-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-9.
• 6 Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the β₂-Adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184-8.
• 7 Hall IP, Wheatley A, Wilding P, Liggett SB. Association of Glu 27 beta2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995; 345: 1213-4.
• 8 Large V, Hellstrom L, Reynisdottir S, Lönnqvist F, Eriksson P, Lannfelt L, Arner P. Human Beta-2 Adrenoceptor gene polymorphism are highly frequent in obesity and associate with altered adipocyte beta-2 Adrenoceptor function. J Clin Invest 1997; 100: 3005-13.
• 9 Rose GA, Blackburn H. Cardiovascular Survey Methods. Geneve: World Health Organization; 1982. 2^nd Ed.
• 10 Terwillinger JD, Ott J. Handbook of human genetic linkage. London: The J Hopkins University Press; 1994: 278-9.
• 11 Kaprio J. Genetic epidemiology. Br Med J 2000; 320: 1257-9.
• 12 Britten MB, Zeiher AM, Scachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245: 315-27.
• 13 Iacoviello L, Zito F, Di Castelnuovo A, de Maat M, Kluft C, Donati MB. Contribution of factor VII, fibrinogen and fibrinolytic components to the risk of ischaemic cardiovascular disease: their genetic determinants. Fibrinolysis & Proteolysis 1998; 12: 259-76.
• 14 Iacoviello L, Di Castelnuovo A, De Knijff P, D’Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. A polymorphism in the coagulation factor VII gene as an inherited protective factor for myocardial infarction. N Engl J Med 1998; 338: 79-85.